Fobelo Lozano, María JoséSerrano Giménez, ReyesCastro Fernández, Manuel2023-01-252023-01-252018http://hdl.handle.net/10668/12442Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess the efficacy of secukinumab in patients with Crohn's disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatory bowel disease. Although the drug has shown to worsen these pathologies, there are no published data of cases in which the patient is first diagnosed with inflammatory bowel disease during secukinumab treatment. We present two cases of emergence of inflammatory bowel disease in patients with plaque psoriasis and ankylosing spondylitis, treated with secukinumab.enIBDSecukinumabadverse effects; clinical trialsepidemiologypathologyAntibodies, Monoclonal, HumanizedFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedPsoriasisYoung Adultresearch article29746636open access10.1093/ecco-jcc/jjy0631876-4479https://academic.oup.com/ecco-jcc/article-pdf/12/9/1131/25571551/jjy063.pdf